For many years, the pharmaceutical company based its reputation on producing medications in India. The same company is currently expanding more quickly than most of its listed competitors, despite having a plant that is no longer in operation and a product mix increasingly dominated by imported speciality medicines. The figures make it reasonable to wonder whether this is still a manufacturer or has evolved into something completely different.
AstraZeneca Pharma India, which has a market capitalisation of about Rs.17,235.25 crore, was trading at Rs.6,894.10, down 0.48% from its previous close of Rs.6,927.10. The stock trades at a P/E of 101.61x based on trailing earnings.
Manufacturing Winds Down As Revenue Climbs
The strong momentum seen in Q1FY26, when revenue rose 35.81% YoY to Rs.526 crore, continued into Q1 FY27, with revenue growing 30% YoY to Rs.683 crore. However, rather than expanding domestic manufacturing capacity alongside this growth, the company has been selling related assets and scaling down operations at its Bengaluru manufacturing facility.
The direction was evident when a shareholder noted that depreciation trends indicated the plant would be completely written off by the December quarter and enquired about the potential savings on manufacturing and personnel costs. Instead of disputing the underlying trend, management focused the conversation on the more recent and rapidly expanding aspects of the company.
Instead of constructing new facilities, AstraZeneca Pharma India has been importing a growing variety of specialty medications from its parent company, which is based in the UK, and its larger global pipeline. The Chairperson of the AGM explained that research and development is an integrated worldwide endeavour, with India being chosen as a market for products only after the parent determines they are suitable for local patients. The move away from internal manufacturing and towards the commercialisation of medications created and, increasingly, produced abroad is supported by this framing.
Oncology and Biopharma Do The Heavy Lifting
With revenue up 26% YoY to Rs.465 crore, or about 68% of Q1 sales, oncology continued to be the single largest driver. Biopharmaceuticals grew 36% YoY to Rs.162 crore in Q1, a sharper pace than the 8% YoY growth recorded for the segment across FY2025-26. The acceleration suggests newer products, rather than the older cardiovascular and antiplatelet portfolio, are starting to contribute more meaningfully to this business.
Rare Diseases revenue was still small at Rs. 14.4 crore but grew roughly 35-fold YoY from a near-zero base. Management has previously flagged rare diseases as an early-stage segment requiring years of investment in diagnosis and awareness before it can approach the 15-16% share of revenue the category commands for AstraZeneca globally.
Sequential, quarter-on-quarter figures for these segments have not been disclosed in the available data, so the comparison here is limited to year-on-year trends. For FY2025-26 as a whole, profit before tax grew 61% YoY to Rs.252 crore, and the company carries no debt, giving it flexibility to keep shifting resources toward its faster-growing specialist portfolio without stretching its balance sheet.
From Domestic Producer To Import-Led Platform
The manufacturing exit is not an isolated cost-cutting decision; it aligns with a strategy management has repeated across recent disclosures. The stated priority is to expand access to innovative, specialist medicines in India by importing from the global portfolio, rather than to protect domestic production. AstraZeneca globally has also set a target of becoming an $80 billion company by 2030, with 20 new medicine launches.
This shift carries its own risks. A company that no longer manufactures domestically becomes more exposed to import costs, currency movements, and the parent’s global allocation decisions than a traditional India-based drugmaker.
Why The Business Model Is Changing
The shift away from manufacturing is best read as a trade-off between control and growth. Running a domestic plant gave AstraZeneca Pharma India cost control and supply independence, but that portfolio grew far slower than the specialist medicines it now imports, oncology alone posting 49% YoY growth in FY2025-26 against roughly 8% YoY for the older biopharma portfolio in the same year.
Winding down the plant frees capital and management attention that were tied up in a low-growth, asset-heavy business and redirects the company toward simply bringing more of its parent’s global pipeline into India. It is, in effect, a bet that acting as a distribution and commercialisation arm for AstraZeneca’s global R&D delivers better growth per rupee of capital than manufacturing ever did, even though it makes the India business more dependent on the parent’s pricing, allocation, and import decisions.
What Should Investors Watch?
Investors should track how oncology’s share of revenue evolves, since a business generating around 68-70% of sales from one therapy area carries concentration risk if a single drug faces pricing or competitive pressure. The pace of the rare diseases scale-up, the extent of cost savings once the Bengaluru plant is fully wound down, and any further one-off items tied to the manufacturing exit are also worth monitoring in coming quarters.